about
Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial.Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.Memantine before Mastectomy Prevents Post-Surgery Pain: A Randomized, Blinded Clinical Trial in Surgical Patients.Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasComparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.Vaginal Lymphoma: A Possible Cause of Genital Hemorrhage.Temozolomide and unusual indications: review of literature.Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapy.Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.Therapeutic drug monitoring and tyrosine kinase inhibitors.Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study.Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GIBrown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study.High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.[Peritoneal mesothelioma: long survival with intraperitoneal chemotherapy, lanreotide and mucolytics].Temozolomide treatment of an adult with a relapsing medulloblastoma.Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.Hibernoma: a clinical model for exploring the role of brown adipose tissue in the regulation of body weight?Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.Cystemustine in recurrent high grade glioma.Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.[Therapeutic strategies and systemic treatment of brain melanoma metastases].Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies][Management of a patient with cancer during all stages of the disease. Symptomatic treatment. Modalities of surveillance. Psychological, ethical and social problems]Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer[Prognostic value of epidermal growth factor receptor]Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer]Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapyA methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancerSentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation
P50
Q24816477-02FA19E4-7243-42AF-A691-B5CFC1FF9A59Q30992559-2C1919FA-4B8D-447B-9F9B-B27F33B3353CQ33368439-56007885-E6F0-4762-AEEC-1A1C8552621BQ33413244-08F4374B-03A8-4D13-A8CF-8A831334875EQ35981095-F13FA457-62A0-4BE9-9814-FB3784B7D0E7Q36196936-E5E6BF21-EF45-42AF-9FBC-61200DFDE969Q37189169-BA6FF947-4950-409C-A7B7-FF6CFB37C6C1Q37417450-D2A17209-79BB-4385-9CB6-77091B71A421Q38028028-582C2A94-2384-4261-B4DF-1B4ED30FAD33Q38282705-FFF7BC85-15E2-4A74-89BA-409E0269FCF5Q38432663-A62FB66B-C6B3-4D46-A70C-AAF9ACFC7C4AQ38434805-7055923D-07DB-4B16-A52B-9E8C6F3902ACQ40103479-0EF0D0E2-9088-4F07-9B90-778AFEA639AFQ41233301-893B7111-04F6-4D85-AC85-CF370A62A3CCQ41846251-E3021371-E5B9-46E6-9F2C-E6992E06ED08Q43083534-01B25F78-8399-40EA-BF12-879FA2BA8805Q44117882-FB330DE8-14FB-4218-B31B-94B5B4CB113DQ44129181-B164EB48-AC47-4B2E-97A5-6BF3056C93D2Q44401526-F19A35FA-F0AC-4489-97E6-A79BF986A3F0Q46073617-DFEF4F3A-3F98-48E6-A807-89760C7BD71AQ46192906-6462DE3E-FAA5-4EFD-8910-E1CF2E4EA18BQ46692178-BDA1A89E-9B79-44D4-AAAF-F45FE60D2DD9Q46991003-221978AA-851A-4DEC-AE8E-7EDCD0425B8EQ47155335-108FF5E3-FAC4-44D8-88AB-C083F3A44F9AQ47203521-B3C3196E-8A82-4C27-BD88-2A5A8D04DDBAQ48485069-BD2E9CF2-0FBC-49CE-9340-40842082ACB6Q48598346-C7C8CB25-52D7-4059-9B5B-B2229010FCA0Q52624073-99D8FF68-6780-46DF-86CF-9F4FF606CB59Q53805931-5F54FFC1-1057-4ED1-8204-899F5195F7E7Q53921120-4569D0D1-1550-45A2-89B4-378707ED5FB3Q55461000-06CBA41C-B9A2-4A0A-8E64-27890ACF86CEQ57130572-964483C1-CBE9-4646-86F4-A9757DB6E790Q58662842-F635B63B-3582-464D-B140-19646CA6445CQ73586584-F085B172-F2B0-46EB-B9D4-F2F4DD0A361CQ75416379-74F877BC-4561-476A-B389-663CB2D46BD3Q79339657-7D9395DC-1095-4219-89F9-F50CC6684EC1Q79404778-EBD23E9A-24C5-4FD0-9A6E-AD523F28694DQ80548300-F23FD2EF-ED97-493D-A328-A150053EDFB5Q80789138-FD9D325A-7E7D-4185-A45E-3D79710F4513Q80800181-4A618EA2-A048-4511-9026-A3EC8719C57C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Xavier Durando
@ast
Xavier Durando
@en
Xavier Durando
@es
Xavier Durando
@nl
type
label
Xavier Durando
@ast
Xavier Durando
@en
Xavier Durando
@es
Xavier Durando
@nl
prefLabel
Xavier Durando
@ast
Xavier Durando
@en
Xavier Durando
@es
Xavier Durando
@nl
P106
P21
P31
P496
0000-0001-6035-3172